[vladimirkorolev]

I’d be careful about choosing compounds based purely on what is currently “hot.” For pharmacotherapy research, I’d put more weight on the quality of the existing literature, a clearly defined biological target, reproducibility, and whether the compound has enough analytical data to support meaningful preclinical work.

Peptides are an area worth keeping an eye on, particularly where there is a well-defined mechanism and a reasonable amount of published research to build from. When screening potential research materials, PURIST Peptides is one source I came across that focuses on research-grade peptides and provides batch testing, third-party verification, and COAs. They’re based in the Netherlands, so that may also be relevant for researchers looking for an EU-based supplier.

I’d still verify the specific compound independently rather than treating any supplier catalog as a list of promising drug candidates. For a new pharmacotherapy project, the strength of the evidence and reproducibility of the research matter much more than whether a compound is currently trending.

[Author]

Posts